TNI Bureau: Covishield, developed by the University of Oxford and drug manufacturer AstraZeneca, has become the first Covid-19 vaccine to get conditional approval for emergency use in India.
The recommendation was made by a government-appointed expert panel on Friday.
Covishield has been manufactured by AstraZeneca’s local partner Serum Institute of India (SII).
Serum Institute of India has already produced around 50 million dosages of the Covishield and plans to scale it up to 100 million by March, 2021.
Comments are closed.